Replimune Group (REPL) Expected to Announce Earnings on Thursday

Replimune Group (NASDAQ:REPL) is expected to issue its quarterly earnings data before the market opens on Thursday, February 13th. Analysts expect the company to announce earnings of ($0.70) per share for the quarter.

Replimune Group (NASDAQ:REPL) last released its earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. On average, analysts expect Replimune Group to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Replimune Group Price Performance

Replimune Group stock opened at $14.06 on Friday. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18. The business’s 50 day simple moving average is $12.50 and its 200 day simple moving average is $11.56. Replimune Group has a 12 month low of $4.92 and a 12 month high of $17.00. The company has a market cap of $961.99 million, a price-to-earnings ratio of -4.61 and a beta of 1.30.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on REPL. HC Wainwright boosted their price objective on Replimune Group from $17.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday, January 22nd. BMO Capital Markets boosted their price target on shares of Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a research report on Wednesday, January 22nd. Finally, Jefferies Financial Group lifted their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, December 4th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $19.14.

Insider Buying and Selling

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $12.42, for a total value of $124,200.00. Following the sale, the chief executive officer now owns 202,014 shares of the company’s stock, valued at $2,509,013.88. This trade represents a 4.72 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Konstantinos Xynos sold 7,246 shares of the business’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the transaction, the insider now directly owns 109,885 shares of the company’s stock, valued at $1,184,560.30. The trade was a 6.19 % decrease in their position. The disclosure for this sale can be found here. 8.80% of the stock is currently owned by insiders.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.